Vijaya Iyer is a freelance science writer for BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, among others.
She holds a PhD in Microbiology from Kansas State University, where her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following the completion of her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University.
She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.
Orion and Propeller Health have established a collaboration to offer a custom sensor and mobile app to digitally monitor medication use with Easyhaler — a metered-dose dry powder inhaler for the treatment of chronic ... Read more
The first generic version of the inhalation treatment Advair Diskus (fluticasone/salmeterol powder) was recently approved by the U.S. Food and Drug Administration for chronic obstructive pulmonary disease (COPD) and asthma patients. ... Read more
Bevespi Aerosphere (glycopyrronium/formoterol fumarate), a therapy developed by AstraZeneca, has been approved by the European Commission as a maintenance treatment for adults with chronic obstructive pulmonary disease (COPD). Bevespi ... Read more
Treatment administration has started in the second part of a Phase 2 trial evaluating the safety and efficacy of Synairgen‘s inhaled therapeutic candidate SNG001 in patients with chronic obstructive pulmonary ... Read more
Inhaling vaporized cannabis does not improve breathlessness or exercise endurance in patients with advanced chronic obstructive pulmonary disease (COPD), according to a small Canadian study. The study reporting the ... Read more